Maxim Group upgraded shares of Galmed Pharmaceuticals (NASDAQ:GLMD) from a hold rating to a buy rating in a research report released on Thursday, March 15th, MarketBeat.com reports. Maxim Group currently has $14.00 target price on the biopharmaceutical company’s stock.
Other analysts have also recently issued research reports about the company. Zacks Investment Research raised Galmed Pharmaceuticals from a hold rating to a buy rating and set a $13.00 price objective for the company in a research report on Wednesday, January 10th. Roth Capital assumed coverage on Galmed Pharmaceuticals in a research report on Wednesday, November 15th. They set a buy rating and a $32.00 price objective for the company. HC Wainwright raised their target price on Galmed Pharmaceuticals from $18.00 to $24.00 and gave the company a buy rating in a report on Monday, February 12th. Finally, ValuEngine upgraded Galmed Pharmaceuticals from a sell rating to a hold rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $20.40.
GLMD opened at $6.00 on Thursday. The firm has a market cap of $93.69, a P/E ratio of -6.12 and a beta of 2.74. Galmed Pharmaceuticals has a 1 year low of $3.61 and a 1 year high of $12.22.
Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. Galmed Pharmaceuticals had a negative net margin of 1,133.55% and a negative return on equity of 133.50%. equities analysts forecast that Galmed Pharmaceuticals will post -0.77 EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. 683 Capital Management LLC raised its holdings in Galmed Pharmaceuticals by 18.2% during the fourth quarter. 683 Capital Management LLC now owns 649,295 shares of the biopharmaceutical company’s stock valued at $5,941,000 after buying an additional 100,000 shares in the last quarter. Meitav Dash Investments Ltd. bought a new position in Galmed Pharmaceuticals during the fourth quarter valued at about $4,357,000. Park West Asset Management LLC raised its holdings in Galmed Pharmaceuticals by 4.4% during the fourth quarter. Park West Asset Management LLC now owns 292,847 shares of the biopharmaceutical company’s stock valued at $2,679,000 after buying an additional 12,347 shares in the last quarter. Sphera Funds Management LTD. bought a new position in Galmed Pharmaceuticals during the fourth quarter valued at about $2,164,000. Finally, J. Goldman & Co LP bought a new position in Galmed Pharmaceuticals during the fourth quarter valued at about $569,000. Institutional investors own 18.86% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/galmed-pharmaceuticals-glmd-upgraded-to-buy-by-maxim-group.html.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.